Jounce Therapeutics (JNCE) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jounce Therapeutics (JNCE) PT Raised to $35 at Baird
March 8, 2018 12:05 PM ESTBaird analyst Michael Ulz raised his price target on Jounce Therapeutics (NASDAQ: JNCE) to $35.00 (from $30.00) while maintaining aanOutperform rating following Q4 results and ICONIC data on track for ASCO. Ulz sees continued momentum.
Ulz commented, "Jounce reported 4Q17 and reiterated preliminary... More
